Alopecia Areata | Pfizer Información Médica

Materiales de Congresos

La información de esta página es seleccionada de materiales de congresos, áreas terapéuticas y de enfermedades. No pretende servir como una descripción general completa de todos los contenidos mencionados

Volver al áreas de Enfermedades

Presentación Oral

Hordinsky M, Hebert A, Gooderham M, Kwon O, Murashkin N, Tran H, Wajsbrot D, Takiya L, Zwillich SH, Wolk R Marzo 29, 2022 AAD 2022 Alopecia Areata

Efficacy and safety of the oral JAK3/TEC inhibitor ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Ver Presentación

Presentación Oral

Mesinkovska N, Shapiro J, King B, Sinclair R, Zhang X, Lynde C, Gubelin Harcha W, Szepietowski JC, Wajsbrot D, Takiya L, Wolk R Marzo 29, 2022 AAD 2022 Alopecia Areata

Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Ver Presentación

Presentación Oral

Sinclair R, Mesinkovska N, Mitra D, Wajsbrot D, Wolk R, King B Marzo 29, 2022 AAD 2022 Alopecia Areata

Improvement in patient reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Ver Presentación

Presentación Oral

Gandhi K, Fridman M, Ray M, Shy M, Mostaghimi A, Bartolome L Marzo 29, 2022 AAD 2022 Alopecia Areata

Looking Beyond Scalp Hair Loss: Factors Influencing Dermatologists’ Assessment of Alopecia Areata Severity

Ver Presentación

Presentación Oral

King B, Szepietowski JC, Farrant P, Hordinsky M, Lejeune A, Zwillich SH, Wajsbrot D, Wolk R Marzo 29, 2022 AAD 2022 Alopecia Areata

Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: results from the ALLEGRO Phase 2b/3, randomized, double-blind, placebo-controlled trial

Ver Presentación

Póster

Holmes S, Rudnicka L, Blauvelt A, Zlotogorski A, Candiani JO, Edwards RA, Sadrarhami MM, Wolk R, Tran H Septiembre 10, 2022 EADV 2022 Alopecia Areata

Association Between Early Eyebrow/Eyelash Assessments and Subsequent Scalp Hair Regrowth in Patients With Alopecia Areata Treated With Ritlecitinib: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Ver Presentación

Póster

Zhang X, Magnolo N, Mizuashi M, Mesinkovska N, Shapiro J, Zhang F, Kerkmann U, Law E, Wolk R, Schaefer G Septiembre 10, 2022 EADV 2022 Alopecia Areata

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Ver Presentación

Póster

Blume-Peytavi U, Harcha JWG, Yang Q, Schmieder GJ, Hordinsky MK, Micali G, Ohyama M, Takiya L, Zhang F, Schaefer G, Wolk R, Kerkmann U Septiembre 10, 2022 EADV 2022 Alopecia Areata

Evaluation of Response to Ritlecitinib (PF-06651600) Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Ver Presentación

Póster

King B, Bergfeld W, Brzewski P, Aşkin Ö, Passeron T, Randhawa S, Law E, Edwards RA, Wolk R, Zwillich SH, Lejeune A Septiembre 10, 2022 EADV 2022 Alopecia Areata

Impact of disease history on the efficacy of ritlecitinib (PF-06651600) in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

Ver Presentación

Póster

Anderson P, Marwaha S, Piercy J, Law EH, Wolk R, Schaefer G, Neary MP Septiembre 10, 2022 EADV 2022 Alopecia Areata

Impact of Scalp Hair Loss on Treatment Patterns and Physician Satisfaction with Disease Control for Alopecia Areata Patients in Europe

Ver Presentación